Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.10)
# 486
Out of 5,090 analysts
232
Total ratings
54.93%
Success rate
11.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $185 → $205 | $169.70 | +20.80% | 12 | Nov 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $8.07 | +135.44% | 5 | Nov 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $178 → $173 | $155.51 | +11.25% | 31 | Nov 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $104.60 | +23.33% | 14 | Oct 16, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $65 → $77 | $46.67 | +64.99% | 3 | Sep 29, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $43.30 | +82.45% | 5 | Sep 17, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $77.26 | -8.10% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $10.59 | +164.40% | 7 | Aug 18, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $20 → $21 | $11.04 | +90.22% | 4 | Aug 18, 2025 | |
| ERAS Erasca | Downgrades: Equal-Weight | $4 → $2 | $3.27 | -38.84% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $7.07 | +83.88% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $9.90 | +990.91% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $36.38 | +51.18% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $27.44 | -12.54% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $93.29 | -8.89% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $29.91 | -9.73% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $11.61 | -56.93% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $65.67 | +2.03% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.69 | +302.76% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.46 | +173.97% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $2.23 | +79.37% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $6.40 | +118.75% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.29 | +51.98% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $3.73 | -19.57% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $2.22 | +532.05% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.98 | +405.05% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $44.36 | -50.41% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $9.55 | +1,454.97% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.06 | +5,560.38% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.28 | +40.19% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $12.34 | +5,153.34% | 6 | May 8, 2020 |
Jazz Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $185 → $205
Current: $169.70
Upside: +20.80%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $8.07
Upside: +135.44%
Neurocrine Biosciences
Nov 11, 2025
Maintains: Overweight
Price Target: $178 → $173
Current: $155.51
Upside: +11.25%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $104.60
Upside: +23.33%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $65 → $77
Current: $46.67
Upside: +64.99%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $43.30
Upside: +82.45%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $77.26
Upside: -8.10%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $10.59
Upside: +164.40%
Contineum Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $11.04
Upside: +90.22%
Erasca
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $3.27
Upside: -38.84%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.07
Upside: +83.88%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $9.90
Upside: +990.91%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $36.38
Upside: +51.18%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $27.44
Upside: -12.54%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $93.29
Upside: -8.89%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $29.91
Upside: -9.73%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $11.61
Upside: -56.93%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $65.67
Upside: +2.03%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $8.69
Upside: +302.76%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.46
Upside: +173.97%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $2.23
Upside: +79.37%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $6.40
Upside: +118.75%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.29
Upside: +51.98%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $3.73
Upside: -19.57%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $2.22
Upside: +532.05%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.98
Upside: +405.05%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $44.36
Upside: -50.41%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $9.55
Upside: +1,454.97%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.06
Upside: +5,560.38%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.28
Upside: +40.19%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $12.34
Upside: +5,153.34%